XBRANE
LIVE

Serial Number

79253207

Owner

Xbrane Biopharma AB

Attorney

Andy I. Corea

Filing Date

Nov 12, 2018

Add to watchlist:

No watchlists yet
View on USPTO

XBRANE Trademark

Serial Number: 79253207 • Registration: 6004520

XBRANE is a trademark filed by Xbrane Biopharma AB on November 12, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Xbrane Biopharma AB

Banvaktsvägen 22

Entity Type: 09

Trademark Details

Filing Date

November 12, 2018

Registration Date

March 10, 2020

Published for Opposition

December 24, 2019

Goods & Services

[ Surgical apparatus and instruments; injection device for pharmaceuticals; injection syringes; injection needles; medical apparatus, namely, automatic infusion and injection devices for administering drugs to humans ]

Scientific and medical research and development; pharmaceutical research and development services; research and development services in the fields of biological similar pharmaceuticals, generic drugs, biotechnology, diagnostics and pharmaceuticals; consultancy services relating to the discovery and evaluation of drugs and chemical compounds having diagnostic properties and therapeutic properties; technical support services, namely, troubleshooting in the nature of diagnosing problems with medical equipment; diagnostic services in the field of troubleshooting biotechnology and pharmaceutical equipment for scientific research purposes; analyzing biotechnology and pharmaceutical equipment for scientific research purposes; development of new technology for others in the field of biotechnology; medical, pharmaceutical and biotechnological laboratory research services; information, consultancy and advisory services relating to scientific and medical research and development, biotechnological and pharmaceutical research and development and medical equipment research and development

[ Pharmaceutical preparations and medical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases, ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions and infectious diseases; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; chemotherapeutics; hormones for medical purposes; pharmaceutical agents for treating metabolic disorders; amino acids for medical purposes; pharmaceutical agents for treating immunity disorders; pharmaceutical agents for treating physically caused lesions; antiviral preparations; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis and bone metastasis ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Feb 21, 2026 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Feb 21, 2026 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 9, 2026 APRE
TEAS SECTION 71 RECEIVED
Oct 3, 2025 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 10, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 31, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 11, 2020 FICS
FINAL DISPOSITION PROCESSED
Jul 11, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 10, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 10, 2020 R.PR
NOTIFICATION PROCESSED BY IB
Jan 3, 2020 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 24, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 24, 2019 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 18, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 18, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 4, 2019 NONP
ASSIGNED TO LIE
Nov 19, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 7, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 9, 2019 GNFN
FINAL REFUSAL E-MAILED
Jul 9, 2019 GNFR
FINAL REFUSAL WRITTEN
Jul 9, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2019 TROA
REFUSAL PROCESSED BY IB
Apr 6, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 20, 2019 RFCS
REFUSAL PROCESSED BY MPU
Mar 20, 2019 RFRR
APPLICATION FILING RECEIPT MAILED
Mar 9, 2019 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 8, 2019 RFCR
NON-FINAL ACTION WRITTEN
Mar 7, 2019 CNRT
ASSIGNED TO EXAMINER
Mar 5, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 5, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 28, 2019 REPR